Guidelines for biomarker testing in colorectal carcinoma (CRC)
Clinical and Translational Oncology, 08/09/2012
Garcia–Alfonso P et al. – For advanced CRC, it is essential to test for KRAS mutation status before administering an anti–EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF, EGFR, PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time.